| Existing Paradigm | siRNA Paradigm | |
|---|---|---|
| Drugs/MOA | Small molecules, MoAb/Antagonists | siRNAs in a delivery vehicle/Silencing |
| Targets | Mainly extracellular targets (Abs) | All targets |
| Selectivity and Potency | Usually low (small molecules) | Highly selective and potent |
| Time to lead ID & Optimization | Long (several years) | Short (few months) |
| Risk | Usually high (small molecules) | Low (following POC of delivery vehicle) |
▲
